Praxis Precision Medicine Stock (NASDAQ: PRAX)

Praxis Precision Medicine (NASDAQ:PRAX) Stock, Quote.Headers.trade-ideas

Praxis Precision Medicine

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The firm's pipeline covers PRAX-114, for the treatment of a broad range of patients suffering from major depressive disorder and post-traumatic stress disorder; PRAX-944, for the treatment of Essential Tremor and Parkinson's Disease; PRAX-562, and PRAX-222, among others.

Philip Morris - logo

News

Price Target

Markets

Trading Ideas

ASAN

BALL

GTLB

PRAX

SPWH

Philip Morris International To Rally More Than 10%? Here Are 10 Top Analyst Forecasts For Wednesday

Biotech

Health Care

General

Praxis Precision Medicines reports positive Phase 2 EMBOLD study results for relutrigine in treating SCN2A and SCN8A developmental and epileptic encephalopathy, showing significant seizure reduction and improvement in patient behavior and communication.

Praxis Precision Medicines Touts Encouraging Data For Mid-Stage Epilepsy Drug

Wall Street, US stocks

Earnings

Analyst Ratings

These Analysts Increase Their Forecasts On Praxis Precision Medicines After Q2 Results

Praxis Precision Medicines, Inc. - Common Stock

Praxis Precision Medicines Inc

Praxsyn Corp

Needham analyst Bernie McTernan reiterates DraftKings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>) with a Buy and maintains $60 price target.

Reiteration

DKNG

Needham Reiterates Buy on DraftKings, Maintains $60 Price Target

TotalEnergies SE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TTE#NYSE">TTE</a>) inked a deal to supply Air France-KLM with up to 1.5 million tons of sustainable aviation fuel (SAF) over the next 10 years, through 2035.
This is one of Air France-KLM&#8217;s largest SAF agreements. This contract builds on a 2022 memorandum of understanding (MoU) for the supply of 800,000 tons of SAF.
By revisiting the agreement, both groups are reinforcing their commitment to reducing the environmental impact of air transport and lowering CO2 emissions as quickly as possible.
Patrick Pouyanné, Chairman and CEO of TotalEnergies, said, &#8220;SAF contributes both to the energy transition of our customers in the aviation sector and to the industrial transition of our refineries. It therefore represents a real &#8216;win-win&#8217; for the future of industry and aviation.&#8221;
&#8220;Securing the volumes of more sustainable aviation fuel needed to decarbonize our activity is a major challenge. This agreement with TotalEnergies is a further step in this direction, and a testament to our long-standing support for the development of SAF production in France and Europe,&#8221; said&nbsp;Benjamin Smith, Chief Executive Officer of Air France-KLM Group.
Notably, TotalEnergies has invested 340 million euros to convert its refinery into a biorefinery. In 2024, the company invested an additional 70 million euros to process up to 100% of waste from the circular economy, with plans to produce sustainable aviation fuel (SAF) by 2025.
Last week, TotalEnergies extended its sales and purchase agreement (SPA) with CNOOC <a target="_blank" href="https://www.benzinga.com//node/40934542" rel="noreferrer noopener">by an additional five years</a>.
Also, the company inked a 10-year deal with BOTAŞ to supply 1.1 million tons of <a target="_blank" href="https://www.benzinga.com/markets/equities/24/09/40919924/totalenergies-expands-in-turkey-with-long-term-lng-agreement" rel="noreferrer noopener">LNG annually starting in 2027.</a>
Apart from this, this month, the company formed a 50/50 joint venture with Adani Green for a 1,150 MW solar project in Gujarat, India. TotalEnergies will invest $444 million,&nbsp;<a target="_blank" href="https://www.benzinga.com/markets/equities/24/09/40681721/totalenergies-invests-in-indian-solar-projects-forms-jv-with-adani-green-energy" rel="noreferrer noopener">boosting its renewable energy strategy</a>.
Investors can gain exposure to the stock via&nbsp;Advisor Managed Portfolios Miller Value Partners Appreciation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MVPA#NYSE">MVPA</a>) and&nbsp;Octane All-Cap Value Energy ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCTA#NASDAQ">OCTA</a>).
Price Action: TTE shares closed lower by 0.07% at $69.09 on Friday.

Equities

Contracts

MVPA

OCTA

TotalEnergies And Air France-KLM Double Down On Sustainability: SAF Deal Paves The Way To Carbon-Free Skies

Needham analyst Bernie McTernan initiates coverage on Flutter Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLUT#NYSE">FLUT</a>) with a Buy rating and announces Price Target of $270.

Initiation

FLUT

Needham Initiates Coverage On Flutter Entertainment with Buy Rating, Announces Price Target of $270

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Corbus Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>) with a Buy and maintains $80 price target.

CRBP

HC Wainwright & Co. Reiterates Buy on Corbus Pharmaceuticals, Maintains $80 Price Target

TD Cowen analyst Andrew Charles reiterates McDonald's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>) with a Hold and maintains $280 price target.

TD Cowen Reiterates Hold on McDonald's, Maintains $280 Price Target

Fortis Inc. ("Fortis" or the "Corporation") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTS#NYSE">FTS</a>) announced today that its wholly owned subsidiary Fortis&nbsp;Energy Caribbean Inc. ("FECI") has agreed to provide a standby commitment (the "Standby Commitment") for a rights offering (the&nbsp;"Rights&nbsp;Offering") by Caribbean Utilities Company, Ltd. ("CUC") (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CUP#TSX">CUP</a>). Pursuant to the Rights Offering, CUC&nbsp;will issue up to an aggregate of 3,822,298 or 10% of its currently issued and outstanding Class&nbsp;A Ordinary Shares (the "CUC Shares"). FECI will exercise the rights issued to it in the Rights Offering and will acquire a minimum of 2,220,422 CUC Shares at a price of US$13.41 per CUC Share for aggregate consideration of US$29,775,859.02. &nbsp;
Subject to certain customary terms and conditions, FECI may acquire up to 1,601,876 additional CUC Shares at the same price pursuant to the Standby Commitment. If there are no other subscribers in the Rights Offering, FECI will acquire a total of 3,822,298 CUC Shares through the Rights Offering and Standby Commitment for aggregate consideration of US$51,257,016.18. Based on the average daily rate of exchange quoted by the Bank of Canada on September 19, 2024, the consideration in Canadian dollars is C$18.19 per CUC Share or aggregate consideration of C$69,527,600.62 should there be no other subscribers in the Rights Offering.
Prior to the Rights Offering, Fortis indirectly owned 22,204,229 CUC Shares representing approximately 58% of the CUC Shares. On closing of the Rights Offering, which is expected to occur on or about November 4, 2024, Fortis will beneficially own approximately 58% of the CUC Shares if the Rights Offering is fully subscribed or approximately 62% of the CUC Shares if there are no other subscribers in the Rights Offering.
The purpose of the Rights Offering is to provide CUC with capital to be used to finance alternative energy projects, ongoing additions and upgrades to its generation, transmission and distribution systems and for general corporate purposes.
Fortis will review its holdings in CUC Shares from time to time and may acquire additional securities or dispose of securities of CUC, in either case, in the open market, by private agreement or otherwise, depending on numerous factors, including without limitation, the availability of securities of CUC, economic conditions, market conditions and other business and investment opportunities available to Fortis.

TSX:CUP

Fortis Subsidiary Commits $51M in Standby for Caribbean Utilities Rights Offering, Boosts Stake to 62%

As a result of the lifting of the stop work order, the Company will proceed with fulfilling the $128 million delivery order issued under the contract.
The lifting of the stop work order does not affect the U.S. Government Accountability Office&rsquo;s consideration of the protest filed earlier this month challenging the award of the contract to the Company.

AVAV

US Army Lifts Stop Work Order It Issued On Contract With Ceiling Value Of $990M With AeroVironment Related To Switchblade Systems - Filing

Andy &amp; Evan, a renowned children's apparel brand, is delighted to announce a special partnership with Paramount Consumer Products to unveil an extraordinary collaboration featuring Nickelodeon's beloved character, SpongeBob SquarePants. The exclusive SpongeBob SquarePants x Andy &amp; Evan collection is set to launch on September 26th, 2024, celebrating the series' 25th anniversary year.
SpongeBob SquarePants, with his infectious positivity and adventurous spirit, has captured the hearts of audiences worldwide. This unique collaboration with Andy &amp; Evan aims to bring the whimsical world of Bikini Bottom to life through a vibrant and stylish apparel line for children. The collection will cater to boys and girls, available in sizes ranging from infant to 14, and will include a variety of clothing and accessories such as outerwear, tees, hoodies, dresses, and collectible bombers.
The timing of this collaboration aligns with Nickelodeon's celebration of SpongeBob SquarePants' 25th anniversary, a year-long extravaganza honoring the iconic character and his enduring impact on pop culture. The SpongeBob x Andy &amp; Evan collection is a fantastic addition to the celebratory events and merchandise commemorating this milestone anniversary.

PARA

Andy & Evan Partner with Paramount Consumer Products, Launch SpongeBob SquarePants Collection for 25th Anniversary

Wyoming&nbsp;assets&nbsp;comprise&nbsp;of the wholly-owned and fully-licensed Sweetwater Plant &nbsp;and a portfolio of uranium mining projects with approximately 175 million pounds of historic resources.
Completion of the Transaction is subject to customary conditions for a transaction of this nature, with closing expected to occur in the&nbsp;fourth quarter&nbsp;of the calendar year 2024.&nbsp;

Uranium Energy Enters Agreement To Acquire 100% Of Rio Tinto's Wyoming Assets; Purchase Price Payable At Closing Is $175M

IDYA

Ideaya Biosciences Announced Interim Phase 2 Trial Data For Darovasertib In Neoadjuvant Uveal Melanoma And A Successful Fda Type C Meeting On Registrational Trial Design For Regulatory Approval

STSS

Sharps Technology Enters Definitive Deals With Institutional Investors For Secured Bridge Loan Financing Of Approx. $3.5M

Guggenheim analyst Vamil Divan initiates coverage on Keros Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KROS#NASDAQ">KROS</a>) with a Buy rating and announces Price Target of $96.

KROS

Guggenheim Initiates Coverage On Keros Therapeutics with Buy Rating, Announces Price Target of $96

Bernstein analyst Adrian Yanoshik downgrades General Motors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) from Outperform to Market Perform and announces $53 price target.

Downgrades

Bernstein Downgrades General Motors to Market Perform, Announces $53 Price Target

TD Cowen analyst Andrew Charles maintains Cava Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAVA#NYSE">CAVA</a>) with a Buy and raises the price target from $115 to $130.

CAVA

TD Cowen Maintains Buy on Cava Group, Raises Price Target to $130

Shares of Granite Point Mortgage Trust Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPMT#NYSE">GPMT</a>) rose sharply in today's pre-market trading after the company announced a third-quarter common and p<a href="https://www.benzinga.com/quote/GPMT/news">referred stock dividends</a>.
After the market close on Friday, Granite Point Mortgage Trust declared a quarterly cash dividend of 5 cents per share of common stock for the third quarter of 2024. The company's board also declared a quarterly cash dividend of 43.75 cents per share of the 7.00% Series A Fixed-to-Floating Rate Cumulative Redeemable Preferred Stock.
Granite Point Mortgage Trust shares gained 3.2% to $2.93 in the pre-market trading.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Nukkleus Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUKK#NASDAQ">NUKK</a>) gained 73.3% to $0.3683 in pre-market trading after gaining over 5% on Friday.</li>
<li>Linkage Global Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGCB#NASDAQ">LGCB</a>) gained 54.1% to $0.6445 in the pre-market trading session after dipping 57% on Friday.</li>
<li>Wheeler Real Estate Investment Trust, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WHLR#NASDAQ">WHLR</a>) rose 42.9% to $19.99 in pre-market trading after dipping more than 25% on Friday.</li>
<li>Nuvve Holding Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVVE#NASDAQ">NVVE</a>) shares rose 30.9% to $5.13 in pre-market trading after tumbling over 16% on Friday.</li>
<li>Garden Stage Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GSIW#NASDAQ">GSIW</a>) gained 26.7% to $1.70 in pre-market trading after dipping 83% on Friday.</li>
<li>Treasure Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGL#NASDAQ">TGL</a>) gained 23.5% to $0.84 in pre-market trading.</li>
<li>Gogoro Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GGR#NASDAQ">GGR</a>) gained 16.4% to $0.60 in pre-market trading after falling 13% on Friday.</li>
<li>Stem, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STEM#NYSE">STEM</a>) rose 12.8% to $0.4006 in pre-market trading after dipping 12% on Friday. Stem recently named David Buzby as interim CEO following John Carrington&#8217;s departure.</li>
<li>AC Immune SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACIU#NASDAQ">ACIU</a>) shares gained 7.1% to $3.95 in pre-market trading.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Jin Medical International Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZJYL#NASDAQ">ZJYL</a>) fell 21.5% to $3.20 in pre-market trading after jumping around 55% on Friday.</li>
<li>PainReform Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRFX#NASDAQ">PRFX</a>) shares fell 21.1% to $0.6080 in pre-market trading. The company recently announced findings regarding the compatibility of sutures in human clinical trials of PRF-110.</li>
<li>SolarMax Technology Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMXT#NASDAQ">SMXT</a>) shares dipped 19.7% to $0.70 in pre-market trading after surging 9% on Friday.</li>
<li>Aditxt, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADTX#NASDAQ">ADTX</a>) fell 19% to $0.31 in pre-market trading following a 4% decline on Friday.</li>
<li>Chijet Motor Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CJET#NASDAQ">CJET</a>) shares declined 18.5% to $2.28 in pre-market trading. Chijet Motor Company announced issuance of ordinary shares to holders of contingent value rights.</li>
<li>CERo Therapeutics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) fell 16% to $0.10 in today's pre-market trading after jumping 37% on Thursday.</li>
<li>Gaxos.ai Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GXAI#NASDAQ">GXAI</a>) shares declined 15.2% to $2.05 in pre-market trading. Gaxos.ai announced exercise of warrants for $3.24 million gross proceeds.</li>
<li>Maxeon Solar Technologies, Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAXN#NASDAQ">MAXN</a>) declined 14.8% to $0.0780 in pre-market trading after the company received Nasdaq delisting notification.</li>
<li>Primega Group Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGHL#NASDAQ">PGHL</a>) shares fell 10.3% to $15.00 in pre-market trading after gaining more than 5% on Friday.</li>
<li>James Hardie Industries plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JHX#NYSE">JHX</a>) shares fell 6% to $39.49 in pre-market trading after gaining more than 8% on Friday.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/09/40962695/jim-cramer-viking-has-many-ships-coming-in">Jim Cramer: Viking Has &#8216;Many Ships Coming In&#8217;</a></li>
</ul>

Pre-Market Outlook

Movers

ACIU

ADTX

CERO

CJET

GPMT

GSIW

GXAI

LGCB

Maxeon Solar Technologies, Ltd. - Ordinary Shares

MAXN

NUKK

NVVE

PGHL

PRFX

SMXT

STEM

WHLR

ZJYL

Why Granite Point Mortgage Trust Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

After weeks of uncertainty, Democratic presidential hopeful Kamala Harris finally put her cryptocurrency cards on the table, eliciting mixed reactions from industry observers.
What happened: At a fundraising event at Wall Street, the vice president<a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40972902/kamala-harris-finally-mentions-crypto-and-that-too-on-wall-street-promises-to-encourage-in"> vowed to protect</a> the interests of emerging technologies like artificial intelligence and digital assets.
Harris' first-ever public mention of cryptocurrencies on the campaign trail got enthusiasts excited, especially the ones favoring her in the election
Anthony Scaramucci, CEO of investment firm SkyBridge Capital, said, "Kamala means Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) in every language."
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Kamala means Bitcoin in every language
&mdash; Anthony Scaramucci (@Scaramucci) <a href="https://twitter.com/Scaramucci/status/1838016216645914765?ref_src=twsrc%5Etfw">September 23, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Another prominent market observer and founder of venture fund Cinneamhain Ventures, Adam Cochran, said Harris proved naysayers wrong with her "pro-digital assets" remark.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">&#x1f440; Progress moves slowly But it does move. There is your first formal statement, directly from Harris that is reasonably pro-digital assets. Proving that the naysayers who thought it not being in her platform was some evil plan, had no idea what they were talking about &#x1f937;&#x200d;&#x2642;&#xfe0f;… <a href="https://t.co/ynldI6RBtK">https://t.co/ynldI6RBtK</a>
&mdash; Adam Cochran (adamscochran.eth) (@adamscochran) <a href="https://twitter.com/adamscochran/status/1837972999045046618?ref_src=twsrc%5Etfw">September 22, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
That said, neutral observers also welcomed Harris' crypto-friendly remark. Coinbase's Chief Policy Officer Faryar Shirzad dubbed the statement "important and constructive."
"We should press for more, but her statement today means a lot and we should recognize that," the executive noted.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">This is an important and constructive statement from <a href="https://twitter.com/KamalaHarris?ref_src=twsrc%5Etfw">@KamalaHarris</a>. It's not nearly as forward leaning as the concrete and visionary positions taken by <a href="https://twitter.com/realDonaldTrump?ref_src=twsrc%5Etfw">@realDonaldTrump</a>, but it's still notable because: &#8211; she recognizes digital asset innovation as being important and on par… <a href="https://t.co/sIzq06a4lU">https://t.co/sIzq06a4lU</a>
&mdash; Faryar Shirzad &#x1f6e1;&#xFE0F; (@faryarshirzad) <a href="https://twitter.com/faryarshirzad/status/1837967033612546429?ref_src=twsrc%5Etfw">September 22, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Jake Chervinsky, Chief Legal Officer at Variant Fund, said, "This is progress and progress is good," although he wanted to know more about her policy.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">This is progress and progress is good… …but "while protecting our consumers and investors" could mean a lot of things. The anti-crypto army uses "consumer protection" as a smoke screen to conceal their attempts to destroy our industry. I, for one, want to see policy details. <a href="https://t.co/Zc1aUdOYzl">https://t.co/Zc1aUdOYzl</a>
&mdash; Jake Chervinsky (@jchervinsky) <a href="https://twitter.com/jchervinsky/status/1838000616829862216?ref_src=twsrc%5Etfw">September 22, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40950912/bitcoins-reserve-asset-appeal-increased-due-to-state-of-us-federal-deficit-and-debt-says-b">Bitcoin&#8217;s Reserve Asset Appeal Increased Due To State Of US Federal Deficit And Debt, Says BlackRock: A Hedge Against &#8216;Possible Future Events&#8217; Affecting The Dollar</a>
However, not everyone was convinced. Pierre Rochard, VP of Research at Riot Platforms, said that Harris was "fully aligned" with anti-cryptocurrency crusader Senator Elizabeth Warren (D-Mass.) on pushing central bank digital currencies and shadow-banning Bitcoin.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Kamala is fully aligned with Elizabeth Warren on pushing a CBDC and shadow-banning Bitcoin, read between the lines here <a href="https://t.co/6elzRi12ht">https://t.co/6elzRi12ht</a>
&mdash; Pierre Rochard (@BitcoinPierre) <a href="https://twitter.com/BitcoinPierre/status/1837964639596171649?ref_src=twsrc%5Etfw">September 22, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Additionally, Ryan Selkis, the founder of on-chain analytics firm Messari, also known for his pro-Trump statements, outrightly dismissed Harris' overture.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">If you believe this, you deserve to work on Wall Street on a soulless CBDC desk. <a href="https://t.co/ezpS6IvPyk">https://t.co/ezpS6IvPyk</a>
&mdash; Ryan Selkis (d/acc) &#x1f1fa;&#x1f1f8; (@twobitidiot) <a href="https://twitter.com/twobitidiot/status/1837948219684233651?ref_src=twsrc%5Etfw">September 22, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Price Action: Bitcoin rallied sharply since Harris&#8217; remarks, climbing as high as $64,660 before relinquishing gains to trade at $63,539.22 as of this writing, according to&nbsp;<a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA..">data from Benzinga Pro</a>.
Check This Out:
<ul>
<li>Lawmakers Made Huge Investments This Year. <a href="https://www.benzinga.com/gov-trades">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Photo created using Shutterstock and Midjourney.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Politics

$BTC

$SOL

Kamala Harris' First Public Mention Of Cryptocurrencies On Campaign Trail Sparks Excitement Among Enthusiasts: 'This Is Progress And Progress Is Good…'

Small Cap Consumer Research analyst Eric Beder maintains Jakks Pacific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAKK#NASDAQ">JAKK</a>) with a Buy and raises the price target from $24 to $30.

JAKK

Small Cap Consumer Research Maintains Buy on Jakks Pacific, Raises Price Target to $30

XOMA Royalty Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XOMA#NASDAQ">XOMA</a>) ("XOMA" or the "Company") today announced its Board of Directors has authorized the following cash dividends to holders of XOMA's Series A and Series B Cumulative Preferred Stock: &nbsp;
Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XOMAP#NASDAQ">XOMAP</a>) shall receive a cash dividend equal to $0.53906 per share.&nbsp;&nbsp;
Holders of depositary shares, each representing 1/1000 of a share of XOMA's 8.375% Series B Cumulative Perpetual Preferred Stock (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XOMAO#NASDAQ">XOMAO</a>), shall receive a cash dividend equal to $0.52344 per depositary share.&nbsp;&nbsp;
The preferred dividends will be paid on or about October 15, 2024, to respective holders of record at the close of business on October 3, 2024.&nbsp;&nbsp;

Dividends

XOMA

XOMAO

XOMAP

XOMA Announces $0.53906 for Series A, $0.52344 for Series B Preferred Dividends, Record Date October 3

From making yearly design changes to moving to a three-year redesign cycle, the evolution of hardware innovation in Apple Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) iPhones indicates that the tech giant is now relying on <a href="https://www.benzinga.com/news/24/09/40780100/apple-intelligence-ready-iphone-16-with-faster-processor-dedicated-camera-button-announced-check-pri">software upgrades more</a>.
What Happened: In its weekly &#8220;Power On&#8221; newsletter, Bloomberg columnist Mark Gurman spoke about the slow pace of hardware innovation, compared to its track record before 2010s.
According to Gurman, Apple&#8217;s yearly redesign schedule was deeply ingrained in its system until the mid-2010s.
However, by the launch of the iPhone X in 2017, Cupertino had moved to a three-year redesign cycle.
Then in 2020 came the iPhone 12, the tech giant's first iPhone to connect to 5G networks.
"After that, the redesign lag got even lengthier. Apple now appears to be working on a half-decade-long cycle," Gurman stated.
See Also: <a href="https://www.benzinga.com/news/24/09/40974511/iphone-15-pro-models-and-iphone-13-discontinued-by-apple-heres-why">iPhone 15 Pro Models and iPhone 13 Discontinued By Apple: Here&#8217;s Why</a>
He noted that the iPhone 16 has a nearly identical look and feel to the iPhone 12. "Apple has added a lot other features between 2020 and 2024, but it's undeniable that the days of frequent hardware changes are over."
While it&#8217;s unclear if this has negatively impacted Apple&#8217;s sales, the company did experience a revenue decline last year, partly due to slower iPhone sales.
However, Gurman notes that a reliable group of customers upgrade every year or two due to the iPhone Upgrade Program, trade-in offers, or carrier installment programs.
For the iPhone 16 series, he said that despite the absence of major hardware upgrades, the iPhone 16 could be a hit product, given the focus on Apple Intelligence.
In fact, according to Gurman, it is a sign that Apple is now relying more on software to sell its new iPhones.
Subscribe to the <a href="https://bztechtrends.beehiiv.com/subscribe">Benzinga Tech Trends newsletter</a> to get all the latest tech developments delivered to your inbox.
Why It Matters: Earlier this month, it was reported that many <a href="https://www.benzinga.com/news/24/09/40785959/iphone-16-fails-to-sway-some-chinese-buyers-im-going-to-buy-huaweis-tri-fold-phone-missing-ai-featur">Chinese buyers were</a> disappointed by the iPhone 16. They cited the lack of AI features in the models as the major reason behind this letdown.
Previously, Apple analyst Ming-Chi Kuo said that <a href="https://www.benzinga.com/tech/24/09/40930388/apple-iphone-16-pre-orders-show-possible-low-demand-one-sign-could-point-to-company-breaking-this-em">iPhone 16 pre-order sales</a> have reached 37 million units, noting that the smartphone's demand could be low.
&#8220;Apple employees can already purchase the iPhone 16 with their employee discount. Typically, employees have had to wait several weeks after the release of new iPhone models before being able to buy. This could be another sign that the early demand for the iPhone 16 is below expectations,&#8221; he stated at the time.
iPhone 16 series has also been facing increasing competition in China as the country's top smartphone maker Huawei Technologies also launched its <a href="https://www.benzinga.com/news/24/09/40845772/huaweis-2-800-tri-fold-phone-has-the-potential-to-eat-apples-lunch-in-china-here-is-how-it-compares">tri-fold phone</a> during the same time as Apple.
Despite these challenges, Wedbush analyst Dan Ives said that a strong start in the demand for iPhone 16 has kept Cupertino on track to hit a <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40971882/as-apples-iphone-16-goes-on-sale-analyst-says-demand-off-to-strong-start-keeping-cu">$4 trillion market cap</a>.
Check out more of Benzinga&#8217;s Consumer Tech coverage by <a href="https://www.benzinga.com/topic/consumer-tech">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/entertainment/24/09/40968348/whats-next-the-future-with-bill-gates-microsoft-co-founder-unveils-behind-the-scenes-of-his?itm_source=parsely-api">‘What's Next? The Future With Bill Gates': Microsoft Co-Founder Unveils Behind The Scenes Of His New Netflix Series</a></li>
</ul>
Photo Courtesy: Apple

Tech

Media

AAPL

Are Big iPhone Overhauls A Thing Of The Past? Apple Shifts Focus To Software Upgrades In New Smartphone Lineup As Major Redesigns Take Backseat

<a href="https://www.ft.com/content/0bb0a4f8-ca72-4bc2-9d87-2dfff3567995" title="https://www.ft.com/content/0bb0a4f8-ca72-4bc2-9d87-2dfff3567995">https://www.ft.com/content/0bb0a4f8-ca72-4bc2-9d87-2dfff3567995</a>

Financial Times Reported Earlier. Novo Nordisk Faces Us Congressional Grilling Over Price Of Weight Loss Drugs

H.C. Wainwright analyst Douglas Tsao maintained a Buy rating on Praxis Precision Medicines (PRAX – Research Report) today and set a price target of...

Buy Rating Affirmed for Praxis Precision Medicines Amid Strategic Drug Development and Trial Optimization

In a report released today, Joon Lee from Truist Financial reiterated a Buy rating on Praxis Precision Medicines (PRAX – Research Report). The comp...

Truist Financial Reaffirms Their Buy Rating on Praxis Precision Medicines (PRAX)

In a report released today, Francois Brisebois from Oppenheimer maintained a Buy rating on Praxis Precision Medicines (PRAX – Research Report), wit...

Praxis Precision Medicines (PRAX) Gets a Buy from Oppenheimer

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Medtronic (MDT – Research Report) and Praxis Precision Medicines ...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Medtronic (MDT) and Praxis Precision Medicines (PRAX)

Needham analyst Ami Fadia has maintained their bullish stance on PRAX stock, giving a Buy rating on August 21. Ami Fadia has given his Buy rating d...

Buy Rating Affirmed for Praxis Precision Medicines Amid Positive Epilepsy Drug Data

The latest update is out from Praxis Precision Medicines (PRAX). Praxis Precision Medicines, Inc. has reported promising results from its EMBOLD st...

Praxis Precision Medicines' Promising EMBOLD Study Outcomes

H.C. Wainwright analyst Douglas Tsao has reiterated their bullish stance on PRAX stock, giving a Buy rating today. Douglas Tsao has given his Buy r...

Buy Rating Affirmed for Praxis Precision Medicines Amid Promising Relutrigine Clinical Data

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Enliven Therapeutics (ELVN – Research Report), Ascen...

Analysts' Top Healthcare Picks: Enliven Therapeutics (ELVN), Ascendis Pharma (ASND)

Douglas Tsao, an analyst from H.C. Wainwright, reiterated the Buy rating on Praxis Precision Medicines (PRAX – Research Report). The associated pri...

Optimistic Outlook for Praxis Precision Medicines: Buy Rating Justified by Strategic Advancements and Positive Trial Results

Small-cap stocks have climbed recently. Here are the ones most poised for further upside

AQST

ASND

BFLY

BYRN

CDNA

CLOV

COMM

CURI

DAVE

ELVN

ESOA

EVER

GTHX

HRTG

HYLN

INSG

JAGGF

OPFI

PSIX

PSNL

SUPV

USAP

Press Releases

Praxis Precision Medicines to Report First Quarter 2024 Financial Results on Monday, May 13, 2024

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2024 Financial Results

Praxis Precision Medicines to Participate in Upcoming Investor Conferences

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Praxis Precision Medicines to Announce Second Quarter 2024 Financial Results and Host Conference Call on Tuesday, August 13, 2024

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2024 Financial Results

Praxis Precision Medicines to Announce Topline Data from the Phase 2 EMBOLD Study of Relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and Epileptic Encephalopathies on September 3, 2024

Praxis Precision Medicines announces positive topline results from the EMBOLD study in SCN2A and 8A developmental epilepsies, highlighting the disease-modifying potential of relutrigine

Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentations

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Praxis Precision Medicine

Praxis Precision Medicine (PRAX) Forecast

Praxis Precision Medicine (NASDAQ:PRAX) Stock, Quote.Headers.trade-ideas